- Current report filing (8-K)
March 16 2012 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act 1934
Date of Report (date of earliest event reported):
March 13, 2012
American Oriental Bioengineering, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
001-32569
|
84-0605867
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1 Liangshuihe First Ave, Beijing E-Town Economic
and Technology Development Area, E-Town,
Beijing, 100176, People’s Republic
of China
(Address of principal executive offices and
zip code)
86-10-5982-2039
(Registrant’s telephone number
including area code)
(Registrant’s former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
£
|
|
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
|
£
|
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
£
|
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
£
|
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
At an audit committee meeting of the Board of
Directors of the Registrant held on March 13, 2012, Ernst & Young Hua Ming, informed the audit committee of certain inconsistencies
noted during the performance of their audit for the year ended December 31, 2011. As a result, management and the audit committee
agreed that the audit committee would immediately commence an independent investigation into the matters identified. Considering
the recent commencement of the investigation, the Company was unable to file its Annual Report on Form 10-K for the 2011 fiscal
year (the “Form 10-K”), by its prescribed due date of March 15, 2012. Although the length of the investigation is uncertain
at this time, the Company will endeavor to file the Form 10-K as soon as possible upon the completion of the investigation.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMERICAN ORIENTAL BIOENGINEERING, INC.
By:
/s/ Tony Liu
Name: Tony Liu
Title: Chairman and Chief Executive Officer
|
Dated: March 16, 2012
3
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024